Pretubulysin: From Hypothetical Biosynthetic Intermediate to Potential Lead in Tumor Therapy

• Jennifer Herrmann,

  Affiliation Helmholtz Institute for Pharmaceutical Research Saarland, Helmholtz Centre for Infection Research and Department of Pharmaceutical Biotechnology, Saarland University, Saarbrücken, Germany

  ⨯
• Yasser A. Elnakady,

  Current address: Chair of Advanced Proteomics and Cytomics Research, College of Science, King Saud University, Riyadh, Saudi Arabia

  Affiliation Helmholtz Institute for Pharmaceutical Research Saarland, Helmholtz Centre for Infection Research and Department of Pharmaceutical Biotechnology, Saarland University, Saarbrücken, Germany

  ⨯
• Romina M. Wiedmann,

  Affiliation Department of Pharmacy, Pharmaceutical Biology, Ludwig-Maximillians-University, Munich, Germany

  ⨯
• Angelika Ullrich,

  Affiliation Institute for Organic Chemistry, Saarland University, Saarbrücken, Germany

  ⨯
• Manfred Rohde,

  Affiliation Department of Medical Microbiology, Helmholtz Centre for Infection Research, Braunschweig, Germany

  ⨯
• Uli Kazmaier,

  Affiliation Institute for Organic Chemistry, Saarland University, Saarbrücken, Germany

  ⨯
• Angelika M. Vollmar,

  Affiliation Department of Pharmacy, Pharmaceutical Biology, Ludwig-Maximillians-University, Munich, Germany

  ⨯
• Rolf Müller

  * E-mail: rolf.mueller@helmholtz-hzi.de

  Affiliation Helmholtz Institute for Pharmaceutical Research Saarland, Helmholtz Centre for Infection Research and Department of Pharmaceutical Biotechnology, Saarland University, Saarbrücken, Germany

  ⨯